STOCK TITAN

Waldencast plc Warrant (WALDW) Stock Price, News & Analysis

WALDW

Waldencast plc Warrant (WALDW) last traded on October 2, 2026. A Form 15-12G filed on October 15, 2026 ends the SEC registration of its shares.

Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
104 195 sessions, October 1, 2025 to October 2, 2026
Largest daily move
+102.9% close of September 18, 2026
1-year change
-82.7% closing prices, October 1, 2025 to October 2, 2026
1-month change
-76% closing prices, September 2, 2026 to October 2, 2026

Company Description

Written before these shares stopped trading.

Waldencast plc (WALDW) is described as a beauty and wellness operating platform within the manufacturing sector, classified under all other miscellaneous chemical product and preparation manufacturing. According to available information, the company focuses on brands and products in the broader beauty and skin health space, with activities that include developing, marketing, and selling beauty-related formulations.

The company is organized into two reportable segments: Obagi Medical and Milk Makeup. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products under the Obagi Medical brand. The Milk Makeup segment involves developing, marketing, and selling cosmetics, skincare, and other beauty products. Based on disclosed segment information, Waldencast plc indicates that a significant portion of its revenue is associated with the Obagi Medical segment, underscoring the importance of skin health products within its overall business.

Waldencast plc is a foreign private issuer that reports to the U.S. Securities and Exchange Commission on Form 20-F and Form 6-K. The company has identified its principal executive office in London, United Kingdom. As a filer under the Securities Exchange Act of 1934, it periodically furnishes current reports on Form 6-K to provide updates on business developments and regulatory or commercial milestones.

Business segments and brand focus

The Obagi Medical segment centers on skin health products. In a Form 6-K current report, Waldencast plc announced that it had issued an announcement titled “Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand.” This highlights that the Obagi Medical segment includes products that may be subject to regulatory review and approval, such as injectable hyaluronic acid gel formulations under the Obagi brand.

The Milk Makeup segment includes cosmetics, skincare, and other beauty products. While detailed product lists are not provided in the available materials, the description of this segment emphasizes that it is focused on beauty and skincare offerings marketed under the Milk Makeup name.

Geographic and industry context

According to prior descriptive information, Waldencast plc generates a majority of its revenue from the North America region. Within the manufacturing sector, and specifically within all other miscellaneous chemical product and preparation manufacturing, its activities relate to the formulation and commercialization of beauty and skin health products, including those that may fall within regulated categories.

Regulatory and reporting profile

As indicated in its Form 6-K filings, Waldencast plc files under Form 20-F and uses Form 6-K to furnish press releases and business updates. One Form 6-K notes that the company provided business and financial updates and described progress on business priorities and initiatives to drive transformation, with a related press release attached as an exhibit. Another Form 6-K references the FDA approval of an Obagi-branded injectable hyaluronic acid gel product, also communicated via an attached company announcement.

These filings show that investors and observers can expect Waldencast plc to use SEC current reports to communicate material developments related to its brands, regulatory milestones, and broader business priorities.

Warrants and WALDW symbol

The symbol WALDW refers to warrants associated with Waldencast plc. The Form 6-K filings provided are identified as “Waldencast plc Warrant Current Report (Foreign Issuer),” indicating that these reports relate to the issuer whose warrants trade under WALDW. The filings themselves focus on company-level developments, and the warrant symbol provides a way for market participants to access exposure linked to Waldencast plc through derivative securities.

Evergreen considerations for investors and observers

From the available information, several structural aspects of Waldencast plc appear central and relatively stable over time:

  • It operates as a beauty and wellness platform within the manufacturing sector.
  • It reports two main segments: Obagi Medical and Milk Makeup.
  • The Obagi Medical segment is associated with skin health products and, in at least one case, an FDA-approved injectable hyaluronic acid gel under the Obagi Medical brand.
  • It is a foreign private issuer that uses Form 20-F and Form 6-K for SEC reporting.
  • Its principal executive office is located in London, United Kingdom.

These elements provide a structural overview of how Waldencast plc presents its business and regulatory profile, without relying on time-sensitive performance metrics.

Stock Performance

$0.0067
No recent trading
Last close: October 2, 2026
-82.7%
1 year to October 2, 2026

Waldencast plc Warrant (WALDW) closed at $0.0067 on October 2, 2026. In the 12 months to October 2, 2026, the price lost 82.7%.

See what a $1,000 investment in WALDW would be worth today

Average down calculator for WALDW

WALDW Metrics & Rankings

Price returns through October 2, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

Waldencast plc Warrant generated $272.1M in revenue in FY2025, retaining a 67.3% gross margin, operating income reached -$217.5M (-80.0% operating margin), and net income was -$229.7M, reflecting a -84.4% net profit margin. Diluted earnings per share stood at -$2.01. The company generated -$12.8M in operating cash flow. The current ratio was 1.70, measuring current assets divided by current liabilities.

$272.1M
Revenue (FY2025)
-$229.7M
Net Income (FY2025)
-$12.8M
Operating Cash Flow

Upcoming Events

No upcoming events scheduled for WALDW.

Short Interest History

Last 12 Months

Short interest in Waldencast plc Warrant (WALDW) currently stands at 8.9 thousand shares, down 86.8% from the previous reporting period. Since November 2025, short interest has decreased by 54.1%.

Days to Cover History

Last 12 Months

Days to cover for Waldencast plc Warrant (WALDW) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 93%. Across the settlements charted above, it has ranged from 1.0 to 36.1 days.

WALDW Company Profile & Sector Positioning

Waldencast plc Warrant (WALDW) .

Investors comparing WALDW often look at related companies in the same sector, including Grupo Financiero Galicia SA (GGAL), Himalaya Shipping Ltd. (HSHP), Southern Copper Corporation (SCCO), HDFC Bank Limited (HDB), and Ares Management Corporation (ARES). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate WALDW's relative position within its industry.

Frequently Asked Questions

Waldencast plc Warrant (WALDW) last traded on October 2, 2026. A Form 15-12G filed on October 15, 2026 ends the SEC registration of its shares.

Waldencast plc Warrant (WALDW) has no recent trading. Its last close was $0.0067 on October 2, 2026.

The FY2025 revenue of Waldencast plc Warrant (WALDW) is $272.1M, from its most recent completed fiscal year.

The FY2025 net income of Waldencast plc Warrant (WALDW) is -$229.7M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Waldencast plc Warrant (WALDW) is -$2.01 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Waldencast plc Warrant (WALDW) is -$12.8M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Waldencast plc Warrant (WALDW) is -84.4% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Waldencast plc Warrant (WALDW) is -80.0% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Waldencast plc Warrant (WALDW) is 67.3% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Waldencast plc Warrant (WALDW), current assets divided by current liabilities, was 1.70 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Waldencast plc Warrant (WALDW) is $183.0M for FY2025, its most recent completed fiscal year.

The operating income of Waldencast plc Warrant (WALDW) is -$217.5M for FY2025, its most recent completed fiscal year. Learn about operating income.